GASC
MCID: GST053
MIFTS: 82

Gastric Cancer (GASC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 57 12 20 72 36 54
Stomach Cancer 12 73 20 72 29 6 42 15
Stomach Carcinoma 12 20 15 70
Gastric Carcinoma 12 54 17
Malignant Neoplasm of Stomach 70 32
Stomach Neoplasms 44 70
Gastric Neoplasm 12 6
Malignant Tumor of Lesser Curve of Stomach 70
Malignant Neoplasm of Body of Stomach 70
Gastric Cancer Intestinal 72
Gastric Cancer, Somatic 57
Adult Stomach Carcinoma 20
Cancer of the Stomach 12
Carcinoma of Stomach 12
Adult Stomach Cancer 20
Gastric Carcinomas 15
Stomach Neoplasm 17
Gastric Cancers 15
Cancer, Gastric 39
Gasc 72

Characteristics:

HPO:

31
gastric cancer:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:10534 DOID:5517
OMIM® 57 613659
KEGG 36 H00018
MeSH 44 D013274
SNOMED-CT via HPO 68 124975008 372143007
UMLS 70 C0024623 C0038356 C0153421 more

Summaries for Gastric Cancer

GARD : 20 Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered " familial." Although the underlying cause of some familial cases is unknown, genetic changes ( mutations ) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene (s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and esophageal cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastric Cancer is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Clopidogrel and Thalidomide have been mentioned in the context of this disorder. Affiliated tissues include stomach, small intestine and lymph node, and related phenotypes are stomach cancer and increased level of l-fucose in urine

Disease Ontology : 12 A gastrointestinal system cancer that is located in the stomach.

OMIM® : 57 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659) (Updated 20-May-2021)

MedlinePlus : 42 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

KEGG : 36 Gastric cancer (GC) is one of the world's most common cancers. According to Lauren's histological classification gastric cancer is divided into two distinct histological groups - the intestinal and diffuse types. Several genetic changes have been identified in intestinal-type GC. The intestinal metaplasia is characterized by mutations in p53 gene, reduced expression of retinoic acid receptor beta (RAR-beta) and hTERT expression. Gastric adenomas furthermore display mutations in the APC gene, reduced p27 expression and cyclin E amplification. In addition, amplification and overexpression of c-ErbB2, reduced TGF-beta receptor type I (TGFBRI) expression and complete loss of p27 expression are commonly observed in more advanced GC. The main molecular changes observed in diffuse-type GCs include loss of E-cadherin function by mutations in CDH1and amplification of MET and FGFR2F.

UniProtKB/Swiss-Prot : 72 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

Wikipedia : 73 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Related Diseases for Gastric Cancer

Diseases in the Gastric Cancer family:

Hereditary Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1344)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 33.7 PIK3CA KRAS FGFR2 ERBB2 APC
2 esophageal cancer 33.1 PIK3CA MIR93 MIR34A MIR21 MIR145 MIR143
3 colorectal cancer 33.1 PIK3CA MUTYH MIR93 MIR34A MIR27A MIR25
4 adenocarcinoma 33.0 PIK3CA KRAS FGFR2 ERBB2 APC
5 small intestine cancer 32.7 MUTYH KRAS ERBB2
6 hepatocellular carcinoma 32.7 PIK3CA MIR93 MIR34A MIR27A MIR25 MIR222
7 lung cancer 32.7 PIK3CA MIR93 MIR34A MIR27A MIR25 MIR222
8 breast cancer 32.5 PIK3CA MUTYH MIR34A MIR27A MIR222 MIR221
9 pancreatic cancer 32.5 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
10 gastrointestinal system disease 32.5 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
11 bladder cancer 32.4 PIK3CA MIR93 MIR34A MIR222 MIR221 MIR21
12 lung cancer susceptibility 3 32.4 PIK3CA MIR21 MIR145 KRAS KLF6 FGFR2
13 adenoma 32.4 PIK3CA MUTYH KRAS APC
14 prostate cancer 32.2 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
15 rectum cancer 32.2 MUTYH MIR21 MIR20A MIR145 MIR143 KRAS
16 gastrointestinal system cancer 32.2 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
17 leukemia, chronic lymphocytic 32.2 MIR34A MIR27A MIR221 MIR21 MIR20A MIR145
18 endometrial cancer 32.1 PIK3CA MUTYH MIR34A MIR27A MIR145 KRAS
19 stomach disease 32.1 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
20 papillary adenocarcinoma 32.0 MIR21 KRAS ERBB2
21 renal cell carcinoma, nonpapillary 32.0 PIK3CA MIR93 MIR34A MIR27A MIR221 MIR21
22 ovarian cancer 32.0 PIK3CA MUTYH MIR34A MIR27A MIR25 MIR222
23 myeloma, multiple 32.0 PIK3CA MIR93 MIR27A MIR25 MIR21 MIR145
24 body mass index quantitative trait locus 11 31.9 MIR93 MIR34A MIR27A MIR222 MIR221 MIR21
25 lynch syndrome 31.9 PIK3CA MUTYH KRAS APC
26 leukemia, acute myeloid 31.9 PIK3CA MIR34A MIR27A MIR222 MIR221 MIR21
27 cholangiocarcinoma 31.9 PIK3CA MIR21 KRAS FGFR2 ERBB2 APC
28 glioblastoma 31.9 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
29 lymphoma, non-hodgkin, familial 31.8 PIK3CA MIR34A MIR27A MIR222 MIR21 MIR20A
30 nasopharyngeal carcinoma 31.8 PIK3CA MIR93 MIR21 MIR143 FGFR2
31 intestinal disease 31.7 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
32 dermatomyositis 31.7 MIR34A MIR222 MIR221 MIR21
33 pancreas disease 31.7 MIR93 MIR34A MIR27A MIR25 MIR221 MIR21
34 glioma 31.7 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
35 kidney cancer 31.7 PIK3CA MIR27A MIR21 MIR20A MIR106B
36 intrahepatic cholangiocarcinoma 31.7 KRAS FGFR2 ERBB2 APC
37 colorectal adenoma 31.7 MUTYH MIR21 KRAS APC
38 diffuse large b-cell lymphoma 31.6 MIR27A MIR222 MIR221 MIR21 MIR145 MIR143
39 disease by infectious agent 31.6 MIR93 MIR34A MIR27A MIR221 MIR21
40 pancreatic ductal adenocarcinoma 31.6 MIR93 MIR222 MIR221 MIR21 MIR145 MIR143
41 cervical cancer 31.5 PIK3CA MIR93 MIR34A MIR21 MIR145 MIR143
42 in situ carcinoma 31.5 PIK3CA MIR143 ERBB2
43 connective tissue disease 31.5 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
44 neuroblastoma 31.5 PIK3CA MIR93 MIR34A MIR221 MIR21 ERBB2
45 arteries, anomalies of 31.4 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
46 colon adenocarcinoma 31.4 PIK3CA MIR21 KRAS ERBB2 APC
47 respiratory system cancer 31.3 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
48 lipoprotein quantitative trait locus 31.3 MIR34A MIR27A MIR222 MIR221 MIR21 MIR145
49 bile duct cancer 31.3 MIR21 MIR145 KRAS ERBB2 APC
50 hematologic cancer 31.3 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer

Symptoms & Phenotypes for Gastric Cancer

Human phenotypes related to Gastric Cancer:

31
# Description HPO Frequency HPO Source Accession
1 stomach cancer 31 HP:0012126
2 increased level of l-fucose in urine 31 HP:0410067

Clinical features from OMIM®:

613659 (Updated 20-May-2021)

UMLS symptoms related to Gastric Cancer:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC ERBB2 FGFR2 IRF1 KRAS MUTYH

Drugs & Therapeutics for Gastric Cancer

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 503)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
2
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
3
Pravastatin Approved Phase 4 81093-37-0 54687
4
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
6
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
7
Nicotine Approved Phase 4 54-11-5 942 89594
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
12
Simethicone Approved Phase 4 8050-81-5
13
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
14
Metronidazole Approved Phase 4 443-48-1 4173
15
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
16
Clarithromycin Approved Phase 4 81103-11-9 84029
17
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
18
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
19
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
20
Pantoprazole Approved Phase 4 102625-70-7 4679
21
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
22
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
23
Iron Approved Phase 4 7439-89-6 23925 29936
24
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
25
Ofloxacin Approved Phase 4 82419-36-1 4583
26
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
27
Lysine Approved, Nutraceutical Phase 4 56-87-1 5962
28
Doxifluridine Investigational Phase 4 3094-09-5
29
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
30 Purinergic P2Y Receptor Antagonists Phase 4
31 Anticholesteremic Agents Phase 4
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
33 Hypolipidemic Agents Phase 4
34 Lipid Regulating Agents Phase 4
35 Soy Bean Phase 4
36 Soybean oil, phospholipid emulsion Phase 4
37 Fat Emulsions, Intravenous Phase 4
38 Anticonvulsants Phase 4
39 Central Nervous System Stimulants Phase 4
40 Anti-Bacterial Agents Phase 4
41 Anti-Infective Agents Phase 4
42 Anti-Arrhythmia Agents Phase 4
43 glutamine Phase 4
44 Hypnotics and Sedatives Phase 4
45 Nicotinic Agonists Phase 4
46 Dopamine Agents Phase 4
47 Dopamine Uptake Inhibitors Phase 4
48 Cytochrome P-450 Enzyme Inhibitors Phase 4
49 Viscum album peptide Phase 4
50 European Mistletoe Phase 4

Interventional clinical trials:

(show top 50) (show all 1818)
# Name Status NCT ID Phase Drugs
1 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
2 Fast-track Surgery Recovery Program With Early Jejunostomy Nutrition Protocol Minimizes Time to Adjuvant Chemotherapy in Patients Undergoing Laparoscopic Gastrectomy for Gastric Cancer Unknown status NCT01766765 Phase 4
3 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
4 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
5 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
6 Efficacy of Perioperative Application of Omega-3 Polyunsaturated Fatty Acids on Postoperative Immunization in Gastric Cancer Patients - A Prospective, Randomized Clinical Trial Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
7 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
8 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
9 Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen Unknown status NCT01271582 Phase 4 Irinotecan, 5FU, leucovorin
10 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
11 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
12 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
13 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
14 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
15 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
16 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia: A Randomized Prospective Comparison of Snares and Injectate in the Resection of Large Sessile Colonic Polyps Completed NCT01471756 Phase 4
18 Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
19 Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
20 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Completed NCT02638584 Phase 4 Ilaprazole;Rabeprazole
21 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
22 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection -a Prospective Randomized Controlled Study Completed NCT01914692 Phase 4 Somatostatin
23 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
24 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
25 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
26 Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy. Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
27 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
28 Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial Completed NCT00576940 Phase 4 Reconvan;Peptisorb
29 Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial. Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
30 A Randomized, Controlled, Double-blind Trial of the Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
31 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
32 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study) Completed NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
33 Comparison of Efficacy of Bismuth Potassium Citrate, Pectin Bismuth Capsules, and Pectin Bismuth Granules in the Treatment of Helicobacter Pylori (Hp) First-line Quadruple Regimen: a Multicenter, Randomized, Prospective, Comparative Clinical Trial Recruiting NCT04209933 Phase 4 Bismuth potassium citrate containing quadruple therapy;Colloidal pectin bismuth capsules containing quadruple therapy;Colloidal pectin bismuth particles A quadruple therapy;Colloidal pectin bismuth particles B quadruple therapy
34 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy
35 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
36 The Use of Fibrin Glue Sealant (Tisseel®) as a Reinforcement of Esophagojejunal Anastomoses Will Decrease the Rate of Anastomotic Leak. Recruiting NCT03733639 Phase 4 Tisseel
37 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
38 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
39 Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer Not yet recruiting NCT04168346 Phase 4 Ferric carboxymaltose;Placebos
40 The Effect of Postoperative Supplemental Parenteral Nutrition (SPN) in Gastric Cancer Patients Who Underwent Gastrectomy: A Multicenter Prospective Randomized Controlled Trial Not yet recruiting NCT04607057 Phase 4 Parenteral Nutrition Solutions
41 Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer Not yet recruiting NCT04591028 Phase 4 Indocyanine green
42 A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication Not yet recruiting NCT04660123 Phase 4 Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
43 An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4 trastuzumab [Herceptin]
44 Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma Unknown status NCT02289547 Phase 3 Capecitabine
45 Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm Unknown status NCT02005809 Phase 3
46 Prospective Phase III Trial Using Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Including Adenocarcinoma of the Esophagogastric Junction Unknown status NCT02381847 Phase 3
47 Comparison of SEEOX and SOX Chemotherapeutic Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients Unknown status NCT02338518 Phase 3 oxaliplatin;etoposide;pharmorubicin;S-1
48 The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer: a Multicenter, Open-label, Randomized Trial Unknown status NCT02423278 Phase 2, Phase 3 S-1+Oxaliplatin
49 Phase 3 Study of Enteral Nutrition Rich in Eicosapentaenoic Acid in Patients Receiving Chemotherapy for Gastric Cancer or Colorectal Cancer Unknown status NCT01048463 Phase 3 Nutriall;LDEPA;Placebo;HDEPA;Chemotherapy
50 A Randomized, Multicenter Phase III Study to Assess the Efficacy of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy Unknown status NCT01224652 Phase 3 Paclitaxel;Irinotecan

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cisplatin
CISPLATIN PWDR
docetaxel
Floxuridine
Fluorouracil
Ifosfamide
irinotecan
Irinotecan hydrochloride
Methotrexate
Methotrexate Sodium

Cochrane evidence based reviews: stomach neoplasms

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Stomach Cancer 29

Anatomical Context for Gastric Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

19
Stomach

MalaCards organs/tissues related to Gastric Cancer:

40
Small Intestine, Lymph Node, Eye, Colon, Breast, T Cells, Liver

Publications for Gastric Cancer

Articles related to Gastric Cancer:

(show top 50) (show all 39976)
# Title Authors PMID Year
1
Genetic alterations of the MYH gene in gastric cancer. 54 6 61 57
15273732 2004
2
Inactivating mutations of the caspase-10 gene in gastric cancer. 54 6 57
11973654 2002
3
Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. 54 6 57
9679752 1998
4
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. 57 6
1317264 1992
5
Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. 57 54 61
8938136 1996
6
Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. 6 61
28875981 2017
7
Biallelic MYH germline mutations as cause of Muir-Torre syndrome. 6 54
19998059 2010
8
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 54 57
18488030 2008
9
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 6
15608678 2005
10
A full genome scan for gastric cancer. 57 61
15635081 2005
11
Gastric cancer originating from bone marrow-derived cells. 57 61
15567866 2004
12
A novel splice-site variant of the base excision repair gene MYH is associated with production of an aberrant mRNA transcript encoding a truncated MYH protein not localized in the nucleus. 54 6
15180946 2004
13
Genetic susceptibility and gastric cancer risk. 57 61
12115538 2002
14
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. 54 57
11419427 2001
15
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. 6 54
11325814 2001
16
Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. 57 54
8882883 1996
17
Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. 6 61
7773929 1995
18
Family history and the risk of stomach and colorectal cancer. 57 61
1606546 1992
19
The effect of fibrin glue on the postoperative lymphatic leakage after D2-lymphadenectomy and gastrectomy in patients with gastric cancer. 42 61
33745452 2021
20
COL5A2 as a potential clinical biomarker for gastric cancer and renal metastasis. 61 42
33607786 2021
21
Difficulty in distinguishing malignant gastric lymphoma from advanced gastric cancer: Focusing on endoscopic findings of the Borrmann type. 42 61
33607858 2021
22
DUAL-ENERGY X-RAY ABSORPTIOMETRY AND CALCULATED FRAX RISK SCORES MAY UNDERESTIMATE OSTEOPOROTIC FRACTURE RISK IN VITAMIN D-DEFICIENT VETERANS WITH HIV INFECTION. 6
26684149 2016
23
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
24
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
25
Identification of Medically Actionable Secondary Findings in the 1000 Genomes. 6
26332594 2015
26
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
27
MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. 6
23361220 2014
28
Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. 6
24733792 2014
29
Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. 6
24728327 2014
30
Personalized genomic disease risk of volunteers. 6
24082139 2013
31
Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability. 6
23108399 2013
32
Colorectal cancer in a monoallelic MYH mutation carrier. 6
23625202 2013
33
Oncogenic ERBB3 mutations in human cancers. 6
23680147 2013
34
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
35
Germline Mutations in the Polyposis-Associated Genes BMPR1A, SMAD4, PTEN, MUTYH and GREM1 Are Not Common in Individuals with Serrated Polyposis Syndrome. 6
23805267 2013
36
Cancer-associated variants and a common polymorphism of MUTYH exhibit reduced repair of oxidative DNA damage using a GFP-based assay in mammalian cells. 6
22926731 2012
37
High prevalence of the c.1227_1228dup (p.Glu410GlyfsX43) mutation in Tunisian families affected with MUTYH-associated-polyposis. 6
22744763 2012
38
Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. 6
22703879 2012
39
MUTYH gene expression and alternative splicing in controls and polyposis patients. 6
22473953 2012
40
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
41
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. 6
22683711 2012
42
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
43
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
44
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
45
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 6
22499344 2012
46
MutYH mutation carriers have increased breast cancer risk. 6
21952991 2012
47
MUTYH-associated colon disease: adenomatous polyposis is only one of the possible phenotypes. A family report and literature review. 6
22158503 2011
48
MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. 61 47
21119604 2011
49
A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. 47 61
21112772 2011
50
Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. 6
21079152 2011

Variations for Gastric Cancer

ClinVar genetic disease variations for Gastric Cancer:

6 (show top 50) (show all 95)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MUTYH NM_012222.2(MUTYH):c.1204C>T (p.Pro402Ser) SNV Pathogenic 5298 rs121908382 GRCh37: 1:45797202-45797202
GRCh38: 1:45331530-45331530
2 MUTYH NM_012222.2(MUTYH):c.1232A>G (p.Gln411Arg) SNV Pathogenic 5299 rs121908383 GRCh37: 1:45797174-45797174
GRCh38: 1:45331502-45331502
3 KLF6 NM_001300.6(KLF6):c.465C>A (p.Ser155Arg) SNV Pathogenic 7574 rs121909144 GRCh37: 10:3824044-3824044
GRCh38: 10:3781852-3781852
4 FGFR2 NM_000141.5(FGFR2):c.799T>C (p.Ser267Pro) SNV Pathogenic 13290 rs121918505 GRCh37: 10:123279633-123279633
GRCh38: 10:121520119-121520119
5 PIK3CA NM_006218.4(PIK3CA):c.3203dup (p.Asn1068fs) Duplication Pathogenic 13658 rs587776802 GRCh37: 3:178952146-178952147
GRCh38: 3:179234358-179234359
6 ERBB2 NM_004448.3(ERBB2):c.2326G>A (p.Gly776Ser) SNV Pathogenic 13879 rs28933369 GRCh37: 17:37880997-37880997
GRCh38: 17:39724744-39724744
7 IRF1 NM_002198.3(IRF1):c.22A>T (p.Met8Leu) SNV Pathogenic 14720 rs121912469 GRCh37: 5:131825149-131825149
GRCh38: 5:132489457-132489457
8 MUTYH NM_012222.2(MUTYH):c.725G>A (p.Arg242His) SNV Pathogenic 140877 rs140342925 GRCh37: 1:45798117-45798117
GRCh38: 1:45332445-45332445
9 APC NM_000038.6(APC):c.1660C>T (p.Arg554Ter) SNV Pathogenic 807 rs137854573 GRCh37: 5:112164586-112164586
GRCh38: 5:112828889-112828889
10 APC NM_000038.6(APC):c.2805C>A (p.Tyr935Ter) SNV Pathogenic 810 rs137854575 GRCh37: 5:112174096-112174096
GRCh38: 5:112838399-112838399
11 APC NM_000038.6(APC):c.3867T>A (p.Cys1289Ter) SNV Pathogenic 545962 rs1554085355 GRCh37: 5:112175158-112175158
GRCh38: 5:112839461-112839461
12 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp) SNV Pathogenic 13272 rs79184941 GRCh37: 10:123279677-123279677
GRCh38: 10:121520163-121520163
13 MUTYH NM_001048174.2(MUTYH):c.1103-2A>G SNV Pathogenic 141282 rs587781628 GRCh37: 1:45797230-45797230
GRCh38: 1:45331558-45331558
14 MUTYH NM_001048174.2(MUTYH):c.305-1G>C SNV Pathogenic 234229 rs372267274 GRCh37: 1:45798843-45798843
GRCh38: 1:45333171-45333171
15 MUTYH NM_001128425.1(MUTYH):c.55C>T (p.Arg19Ter) SNV Pathogenic 127845 rs587780088 GRCh37: 1:45800165-45800165
GRCh38: 1:45334493-45334493
16 APC NM_000038.6(APC):c.70C>T (p.Arg24Ter) SNV Pathogenic 184702 rs145945630 GRCh37: 5:112090657-112090657
GRCh38: 5:112754960-112754960
17 APC NM_000038.6(APC):c.637C>T (p.Arg213Ter) SNV Pathogenic 140952 rs587781392 GRCh37: 5:112116592-112116592
GRCh38: 5:112780895-112780895
18 APC NM_000038.6(APC):c.646C>T (p.Arg216Ter) SNV Pathogenic 127312 rs62619935 GRCh37: 5:112128143-112128143
GRCh38: 5:112792446-112792446
19 APC NM_000038.6(APC):c.694C>T (p.Arg232Ter) SNV Pathogenic 42248 rs397515734 GRCh37: 5:112128191-112128191
GRCh38: 5:112792494-112792494
20 APC NM_000038.6(APC):c.847C>T (p.Arg283Ter) SNV Pathogenic 184999 rs786201856 GRCh37: 5:112151204-112151204
GRCh38: 5:112815507-112815507
21 APC NM_000038.6(APC):c.933+1G>A SNV Pathogenic 233970 rs876660765 GRCh37: 5:112151291-112151291
GRCh38: 5:112815594-112815594
22 FGFR2 NM_000141.5(FGFR2):c.1150G>A (p.Gly384Arg) SNV Pathogenic 478046 rs1554927408 GRCh37: 10:123274768-123274768
GRCh38: 10:121515254-121515254
23 FGFR2 NM_000141.5(FGFR2):c.1124A>G (p.Tyr375Cys) SNV Pathogenic 13277 rs121913478 GRCh37: 10:123274794-123274794
GRCh38: 10:121515280-121515280
24 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic 13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
25 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
26 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Pathogenic 39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
27 KRAS NM_004985.5(KRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic 12582 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
28 MUTYH NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp) SNV Pathogenic 5294 rs36053993 GRCh37: 1:45797228-45797228
GRCh38: 1:45331556-45331556
29 MUTYH NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp) SNV Pathogenic 5294 rs36053993 GRCh37: 1:45797228-45797228
GRCh38: 1:45331556-45331556
30 MUTYH NM_001048174.2(MUTYH):c.452A>G (p.Tyr151Cys) SNV Pathogenic 5293 rs34612342 GRCh37: 1:45798475-45798475
GRCh38: 1:45332803-45332803
31 KRAS NM_004985.5(KRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic 12584 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
32 FGFR2 NM_022970.3(FGFR2):c.314A>G (p.Tyr105Cys) SNV Pathogenic 449024 rs1434545235 GRCh37: 10:123325014-123325014
GRCh38: 10:121565500-121565500
33 FGFR2 NM_000141.5(FGFR2):c.1025G>A (p.Cys342Tyr) SNV Pathogenic 13263 rs121918487 GRCh37: 10:123276892-123276892
GRCh38: 10:121517378-121517378
34 CASP10 NM_001230.5(CASP10):c.440T>C (p.Met147Thr) SNV Pathogenic 7768 rs121909776 GRCh37: 2:202052521-202052521
GRCh38: 2:201187798-201187798
35 CASP10 NM_001230.5(CASP10):c.685-2146C>T SNV Pathogenic 7766 rs121909775 GRCh37: 2:202070652-202070652
GRCh38: 2:201205929-201205929
36 APC NM_000038.6(APC):c.3199C>T (p.Gln1067Ter) SNV Pathogenic 803 rs137854571 GRCh37: 5:112174490-112174490
GRCh38: 5:112838793-112838793
37 APC NM_000038.6(APC):c.3359G>A (p.Gly1120Glu) SNV Pathogenic 802 rs28933379 GRCh37: 5:112174650-112174650
GRCh38: 5:112838953-112838953
38 FGFR2 NM_000141.5(FGFR2):c.758C>G (p.Pro253Arg) SNV Pathogenic 13273 rs77543610 GRCh37: 10:123279674-123279674
GRCh38: 10:121520160-121520160
39 FGFR2 NM_000141.5(FGFR2):c.1032G>A (p.Ala344=) SNV Pathogenic 13268 rs121918491 GRCh37: 10:123276885-123276885
GRCh38: 10:121517371-121517371
40 NRAS NM_002524.5(NRAS):c.37G>A (p.Gly13Ser) SNV Likely pathogenic 376221 rs121434595 GRCh37: 1:115258745-115258745
GRCh38: 1:114716124-114716124
41 CTNNB1 NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr) SNV Likely pathogenic 375894 rs121913403 GRCh37: 3:41266113-41266113
GRCh38: 3:41224622-41224622
42 TP53 NM_000546.6(TP53):c.847C>T (p.Arg283Cys) SNV Likely pathogenic 127824 rs149633775 GRCh37: 17:7577091-7577091
GRCh38: 17:7673773-7673773
43 CDH1 NM_004360.5(CDH1):c.2494G>A (p.Val832Met) SNV Likely pathogenic 12246 rs35572355 GRCh37: 16:68867247-68867247
GRCh38: 16:68833344-68833344
44 FANCI NM_001113378.2(FANCI):c.1804C>T (p.Arg602Ter) SNV Likely pathogenic 929725 GRCh37: 15:89828432-89828432
GRCh38: 15:89285201-89285201
45 MUTYH NM_001048174.2(MUTYH):c.850-2A>G SNV Likely pathogenic 41766 rs77542170 GRCh37: 1:45797760-45797760
GRCh38: 1:45332088-45332088
46 FGFR2 NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu) SNV Likely pathogenic 374817 rs1057519044 GRCh37: 10:123276904-123276904
GRCh38: 10:121517390-121517390
47 CDH1 NM_004360.5(CDH1):c.1296C>G (p.Asn432Lys) SNV Likely pathogenic 186937 rs187862045 GRCh37: 16:68847374-68847374
GRCh38: 16:68813471-68813471
48 APC NM_000038.6(APC):c.1312+3A>G SNV Likely pathogenic 217924 rs863225311 GRCh37: 5:112155044-112155044
GRCh38: 5:112819347-112819347
49 CTNNB1 NM_001904.4(CTNNB1):c.109T>C (p.Ser37Pro) SNV Likely pathogenic 376234 rs121913228 GRCh37: 3:41266112-41266112
GRCh38: 3:41224621-41224621
50 CTNNB1 NM_001904.4(CTNNB1):c.118A>G (p.Thr40Ala) SNV Likely pathogenic 376237 rs1057519836 GRCh37: 3:41266121-41266121
GRCh38: 3:41224630-41224630

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

72 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036 rs140029598
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028 rs121913530
16 KRAS p.Gly13Asp VAR_016029 rs112445441
17 KRAS p.Ala59Thr VAR_016030 rs121913528
18 KRAS p.Lys5Asn VAR_064849 rs104894361
19 MUTYH p.Pro402Ser VAR_026049 rs121908382

Cosmic variations for Gastric Cancer:

9 (show top 50) (show all 46209)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94780361 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 48
2 COSM131486960 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 48
3 COSM140706619 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.499G>A p.A167T 18:25226759-25226759 48
4 COSM94777296 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 48
5 COSM131495211 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 48
6 COSM140704933 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1625G>A p.R542H 18:25225633-25225633 48
7 COSM94795709 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 48
8 COSM94788727 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 48
9 COSM140712668 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.-218G>A p.? 18:25227475-25227475 48
10 COSM131483683 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 48
11 COSM131502188 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 48
12 COSM140717636 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2774T>G p.V925G 18:25224484-25224484 48
13 COSM89892679 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 48
14 COSM99686061 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 48
15 COSM96892872 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 48
16 COSM92495186 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.971G>A p.R324Q 12:6669044-6669044 48
17 COSM90523509 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 48
18 COSM98293254 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2533G>A p.A845T 20:33791485-33791485 48
19 COSM84509305 ZNF276 stomach,NS,carcinoma,adenocarcinoma c.*677T>G p.? 16:89738923-89738923 48
20 COSM102042239 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5456G>T p.R1819L 16:72794484-72794484 48
21 COSM149288723 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 48
22 COSM149261321 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 48
23 COSM102020152 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-7323C>T p.? 16:72958288-72958288 48
24 COSM87271088 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 48
25 COSM87291716 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 48
26 COSM87290698 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 48
27 COSM149332052 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 48
28 COSM87280547 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 48
29 COSM102040971 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8386C>A p.? 16:72959351-72959351 48
30 COSM87291652 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 48
31 COSM87296752 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 48
32 COSM149318848 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 48
33 COSM149318790 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 48
34 COSM102042308 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1811G>T p.G604V 16:72798129-72798129 48
35 COSM149315912 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 48
36 COSM102030210 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8100G>A p.? 16:72959065-72959065 48
37 COSM102048038 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.3187G>C p.G1063R 16:72796753-72796753 48
38 COSM89893344 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 48
39 COSM136835352 YES1 stomach,NS,carcinoma,adenocarcinoma c.365G>A p.R122K 18:751726-751726 48
40 COSM152021882 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 48
41 COSM143039512 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
42 COSM145026456 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
43 COSM85235472 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
44 COSM128450026 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
45 COSM126971185 YAP1 stomach,NS,carcinoma,adenocarcinoma c.-179C>G p.? 11:102114178-102114178 48
46 COSM133271379 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
47 COSM127996054 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
48 COSM90945716 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
49 COSM97252932 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 48
50 COSM101975785 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 48

Copy number variations for Gastric Cancer from CNVD:

7 (show top 50) (show all 694)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13401 1 1 2300000 Gain SLC35E2A Gastric cancer
2 13782 1 1 39600000 Gain LCK Gastric cancer
3 13783 1 1 39600000 Gain MDS2 Gastric cancer
4 13784 1 1 39600000 Gain PAX7 Gastric cancer
5 13785 1 1 39600000 Gain PRDM16 Gastric cancer
6 13786 1 1 39600000 Gain RPL22 Gastric cancer
7 13787 1 1 39600000 Gain SDHB Gastric cancer
8 13988 1 102200000 107200000 Loss AMY1A Gastric cancer
9 13989 1 102200000 107200000 Loss AMY2A Gastric cancer
10 19425 1 150222010 150233338 Amplification S100A10 Gastric cancer
11 22648 1 168031174 168088853 Amplification C1orf112 Gastric cancer
12 22794 1 168899937 168975165 Amplification PRRX1 Gastric cancer
13 24343 1 178867796 179122103 Amplification XPR1 Gastric cancer
14 25997 1 195319997 195382287 Amplification ASPM Gastric cancer
15 26293 1 198787930 198856485 Amplification KIF14 Gastric cancer
16 27965 1 216525252 216577948 Amplification RRP15 Gastric cancer
17 28583 1 223655827 223682407 Amplification LBR Gastric cancer
18 29302 1 2300000 5400000 Gain TP73 Gastric cancer
19 29303 1 2300000 5400000 Gain WRAP73 Gastric cancer
20 29725 1 234780594 234834437 Amplification HEATR1 Gastric cancer
21 30108 1 240078158 240119671 Amplification EXO1 Gastric cancer
22 30593 1 244770489 244796186 Amplification TFB2M Gastric cancer
23 37702 1 938709 939782 Copy number ISG15 Gastric cancer
24 37787 1 94700000 99700000 Loss DPYD Gastric cancer
25 38140 10 1 135006516 Loss Gastric cancer
26 40043 10 123336181 123337713 Amplification FGFR2 Gastric cancer
27 40401 10 127500000 130600000 Gain Gastric cancer
28 41839 10 24600000 135534747 Loss Gastric cancer
29 45622 10 73000000 81800000 Amplification PSAP Gastric cancer
30 48318 11 1 135006516 Gain Gastric cancer
31 49710 11 110400000 130800000 Gain Gastric cancer
32 49997 11 112500000 130800000 Gain Gastric cancer
33 53360 11 2800000 10700000 Gain CDKN1C Gastric cancer
34 53361 8 145646122 145661839 Gain CYHR1 Gastric cancer
35 53362 8 145669924 145672526 Gain FOXH1 Gastric cancer
36 53363 11 2800000 10700000 Gain KCNQ1 Gastric cancer
37 53364 11 2800000 10700000 Gain KCNQ1DN Gastric cancer
38 53365 8 145662545 145670307 Gain KIFC2 Gastric cancer
39 53366 11 2800000 10700000 Gain SLC22A18 Gastric cancer
40 53367 11 2800000 10700000 Gain SLC22A18AS Gastric cancer
41 54234 11 40200000 42900000 Amplification LRRC4C Gastric cancer
42 56156 11 57265297 57267459 Copy number SELENOH Gastric cancer
43 56517 11 59900000 61700000 Gain PGA5 Gastric cancer
44 58503 11 68100000 70400000 Amplification CCND1 Gastric cancer
45 58504 11 68100000 70400000 Amplification FGF3 Gastric cancer
46 58651 11 69161019 69306967 Amplification CCND1 Gastric cancer
47 58653 11 69161019 69306967 Amplification FGF19 Gastric cancer
48 58655 11 69161019 69306967 Amplification FGF4 Gastric cancer
49 58657 11 69161019 69306967 Amplification LTO1 Gastric cancer
50 59248 11 73719009 73787150 Amplification PGM2L1 Gastric cancer

Expression for Gastric Cancer

Search GEO for disease gene expression data for Gastric Cancer.

Pathways for Gastric Cancer

Pathways related to Gastric Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Gastric cancer hsa05226

Pathways related to Gastric Cancer according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 PIK3CA KRAS IRF1 FGFR2 ERBB2 APC
2 12.68 PIK3CA KRAS FGFR2 ERBB2 APC
3
Show member pathways
12.63 PIK3CA KRAS FGFR2 ERBB2 APC
4
Show member pathways
12.56 PIK3CA KRAS FGFR2 ERBB2 APC
5
Show member pathways
12.34 PIK3CA KRAS FGFR2 ERBB2
6
Show member pathways
12.32 PIK3CA KRAS IRF1 ERBB2
7
Show member pathways
12.27 PIK3CA KRAS FGFR2 ERBB2 APC
8
Show member pathways
12.2 MIR222 MIR221 MIR20A MIR106B
9
Show member pathways
12.2 PIK3CA KRAS FGFR2 ERBB2 APC
10 12.09 PIK3CA MIR21 KRAS ERBB2
11
Show member pathways
12.08 PIK3CA KRAS FGFR2 ERBB2 CASP10
12 11.96 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
13 11.89 PIK3CA KRAS FGFR2 APC
14 11.68 PIK3CA KRAS ERBB2 APC
15
Show member pathways
11.64 PIK3CA KRAS CASP10
16 11.3 PIK3CA KRAS FGFR2 ERBB2
17 11.2 MIR93 MIR27A MIR25 MIR222 MIR221 MIR145
18 11.02 KRAS ERBB2 APC

GO Terms for Gastric Cancer

Cellular components related to Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 MIR93 MIR27A MIR25 MIR222 MIR221 MIR21
2 extracellular vesicle GO:1903561 9.23 MIR93 MIR34A MIR27A MIR222 MIR221 MIR21

Biological processes related to Gastric Cancer according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.05 MIR93 MIR221 MIR21 IRF1 APC
2 actin cytoskeleton organization GO:0030036 9.93 PIK3CA MIR145 MIR143 KRAS
3 negative regulation of gene expression GO:0010629 9.93 MIR93 MIR34A MIR27A MIR21 MIR20A MIR106B
4 negative regulation of cell migration GO:0030336 9.92 MIR93 MIR34A MIR21 MIR145
5 negative regulation of inflammatory response GO:0050728 9.89 MIR222 MIR221 MIR20A MIR145
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 MIR27A MIR222 MIR221 MIR21 FGFR2
7 positive regulation of osteoblast differentiation GO:0045669 9.83 MIR27A MIR21 MIR20A
8 negative regulation of protein kinase B signaling GO:0051898 9.82 MIR34A MIR20A MIR145
9 positive regulation of epithelial to mesenchymal transition GO:0010718 9.8 MIR222 MIR221 MIR21
10 negative regulation of angiogenesis GO:0016525 9.8 MIR34A MIR222 MIR21 MIR145 MIR143 MIR106B
11 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.77 MIR93 MIR222 MIR221
12 negative regulation of sprouting angiogenesis GO:1903671 9.76 MIR34A MIR221 MIR20A
13 negative regulation of vascular endothelial growth factor production GO:1904046 9.73 MIR93 MIR34A MIR20A
14 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.73 MIR21 MIR20A MIR145 MIR106B
15 regulation of ERK1 and ERK2 cascade GO:0070372 9.72 MIR145 FGFR2 ERBB2
16 positive regulation of protein kinase B signaling GO:0051897 9.7 PIK3CA MIR222 MIR221 MIR21 MIR143 FGFR2
17 mesodermal cell differentiation GO:0048333 9.68 MIR145 FGFR2
18 positive regulation of axon regeneration GO:0048680 9.67 MIR222 MIR221
19 negative regulation by host of viral genome replication GO:0044828 9.67 MIR222 MIR221
20 regulation of microtubule-based process GO:0032886 9.67 ERBB2 APC
21 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.67 MIR221 MIR21 MIR20A MIR143
22 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.66 MIR222 MIR221
23 angiotensin-activated signaling pathway GO:0038166 9.66 MIR145 MIR143
24 negative regulation of regulatory T cell differentiation GO:0045590 9.65 MIR21 IRF1
25 negative regulation of cell adhesion molecule production GO:0060354 9.65 MIR222 MIR221 MIR20A
26 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.65 MIR27A MIR222 MIR221 MIR21 MIR20A
27 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.64 MIR27A MIR21
28 aorta smooth muscle tissue morphogenesis GO:0060414 9.63 MIR145 MIR143
29 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.61 MIR20A MIR143
30 regulation of phenotypic switching GO:1900239 9.61 MIR145 MIR143
31 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.58 MIR222 MIR221
32 negative regulation of interleukin-21 production GO:0032705 9.58 MIR222 MIR221 MIR21
33 positive regulation of Schwann cell migration GO:1900149 9.57 MIR222 MIR221
34 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.54 MIR222 MIR221
35 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.52 MIR222 MIR221
36 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.51 MIR145 MIR143
37 miRNA mediated inhibition of translation GO:0035278 9.5 MIR27A MIR222 MIR221 MIR21 MIR20A MIR145
38 gene silencing by miRNA GO:0035195 9.36 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221

Molecular functions related to Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.56 MIR93 MIR34A MIR27A MIR21 MIR20A MIR145
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221

Sources for Gastric Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
12